To announce the completion status of execution
of the stock repurchase
Date of events
2022/08/09
To which item it meets
paragraph 35
Statement
1.Originally determined ceiling on total monetary amount of the share
repurchase (NTD):1,528,090,000
2.Originally scheduled period for the repurchase:2022/06/10~2022/08/09
3.Originally determined no.of shares to be repurchased (shares):3,000,000
4.Originally determined repurchase price range (NTD):35.00~52.50
5.Actual period of the current repurchase:2022/06/10~2022/08/09
6.No.of shares currently repurchased (shares):3,000,000
7.Total monetary amount of shares currently repurchased (NTD):110,556,086
8.Current average repurchase price per share (NTD):36.85
9.Cumulative no.of the company's own shares held (shares):3,000,000
10.Cumulative no.of the company's own shares as a percentage of the total
no.of the company's issued shares (%):0.70%
11.Reason for non-completion of the current share repurchase:N.A.
12.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Adimmune Corporation published this content on 09 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2022 09:25:07 UTC.
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.